Intervention not reported
Duration of mechanical ventilation (days) · Preterm neonates with respiratory distress
1 finding from 1 review
Intervention not reported
Duration of supplemental oxygen (days) · Preterm neonates with respiratory distress
1 finding from 1 review
Intervention not reported
Hyperglycaemia · Preterm neonates with respiratory distress
The intervention probably leads to lower hyperglycaemia (moderate certainty).
1 finding from 1 review
Intervention not reported
Patent ductus arteriosus · Preterm neonates with respiratory distress
The intervention probably leads to higher patent ductus arteriosus (moderate certainty).
1 finding from 1 review
Intervention not reported
BPD at 36 weeks' postmenstrual age · Preterm neonates with respiratory distress
The intervention showed no clear difference in BPD at 36 weeks' postmenstrual age (moderate certainty).
1 finding from 1 review
Intervention not reported
Change in disability after one year · people with chronic inflammatory demyelinating polyradiculoneuropathy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Change in grip strength · patients with chronic inflammatory demyelinating polyradiculoneuropathy
1 finding from 1 review
Sleeplessness · patients with chronic inflammatory demyelinating polyradiculoneuropathy
Monthly pulsed high‐dose dexamethasone may leads to lower sleeplessness compared with oral prednisolone (low certainty).
1 finding from 1 review
Moon facies · patients with chronic inflammatory demyelinating polyradiculoneuropathy
Monthly pulsed high‐dose dexamethasone probably leads to lower moon facies compared with oral prednisolone (moderate certainty).
1 finding from 1 review
Intervention not reported
Change in impairment after 12 weeks (excluding those who did not complete the study) NIS score (range 0 to 280) · people with chronic inflammatory demyelinating polyradiculoneuropathy
1 finding from 1 review
Intervention not reported
Change in impairment after 12 weeks (including those who did not complete the study) NIS (range 0 to 280) · people with chronic inflammatory demyelinating polyradiculoneuropathy
1 finding from 1 review
Intervention not reported
Number of participants improved after 12 weeks (excluding those who did not complete the study) NIS score (range 0 to 280) · people with chronic inflammatory demyelinating polyradiculoneuropathy
It is very uncertain whether the intervention changes number of participants improved after 12 weeks (excluding those who… (very low certainty).
1 finding from 1 review
Intervention not reported
Number of participants improved after 12 weeks (including those who did not complete the study) NIS (range 0 to 280) · people with chronic inflammatory demyelinating polyradiculoneuropathy
It is very uncertain whether the intervention changes number of participants improved after 12 weeks (including those who… (very low certainty).
1 finding from 1 review
Change in disability after one year · patients with chronic inflammatory demyelinating polyradiculoneuropathy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Remission · patients with chronic inflammatory demyelinating polyradiculoneuropathy
Monthly pulsed high‐dose dexamethasone probably leads to higher remission at 12 months compared with oral prednisolone (moderate certainty).
1 finding from 1 review
≥ 1 point improvement on INCAT disability score at 12 months · patients with chronic inflammatory demyelinating polyradiculoneuropathy
Monthly pulsed high‐dose dexamethasone may leads to higher ≥ 1 point improvement on INCAT disability score at 12 months compared with oral prednisolone (low certainty).
1 finding from 1 review
Change in MRC sum score · patients with chronic inflammatory demyelinating polyradiculoneuropathy
1 finding from 1 review
Participants able to reduce corticosteroid or IVIg dose by more than 20% · people with CIDP
Methotrexate showed no clear difference in participants able to reduce corticosteroid or IVIg dose by more than… compared with placebo (moderate certainty).
1 finding from 1 review
Change in disability after 26 or more weeks Overall Neuropathy Limitation Scale. Scale from: 0 to 12. · people with CIDP
1 finding from 1 review
Change in disability after 26 or more weeks Amsterdam Linear Disability Scale. Scale from: 0 to 100. · people with CIDP
1 finding from 1 review